Iterion Therapeutics

IN THE PRESS

Business

Iterion Therapeutics Hires Jean Chang as Chief Operating Officer

July 14, 2021

·

4 min read

Drug Development

Iterion Therapeutics Confirms Safety of Tegavivint Following Completion of Enrollment in Phase 1/2a Expansion Study in Patients with Desmoid Tumors

April 13, 2021

·

4 min read

Lone Star Bio

Iterion Therapeutics Secures $17 Million to Advance Development of Tegavivint in Multiple Tumor Settings

February 16, 2021

·

4 min read

Business

Apollomics, Inc. and Iterion Therapeutics Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Tegavivint in Greater China

February 10, 2021

·

5 min read

Drug Development

Iterion Therapeutics Initiates Enrollment of Phase 2a Dose Expansion Study of Tegavivint in Patients with Desmoid Tumors

July 28, 2020

·

4 min read

Drug Development

Iterion Therapeutics Initiates Phase I Clinical Study of Tegavivint in Patients with Desmoid Tumors

December 5, 2018

·

2 min read

JOBS